Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need ... Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell ...

Key Business Updates BRUKINSA ® (zanubrutinib) is an orally available, small molecule inhibitor of BTK designed to deliver ...

BeiGene, Ltd. ( (BGNE) ) has released its Q3 earnings. Here is a breakdown of the information BeiGene, Ltd. presented to its investors.

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...

“BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax ... with treatment-naïve chronic lymphocytic leukemia/small lymphocytic ...

in combination with BRUKINSA for patients with treatment-naïve CLL/SLL BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class ...